MX2017011009A - Modulacion de la expresion de apolipoproteina c-iii (apociii) en poblaciones con lipodistrofia. - Google Patents
Modulacion de la expresion de apolipoproteina c-iii (apociii) en poblaciones con lipodistrofia.Info
- Publication number
- MX2017011009A MX2017011009A MX2017011009A MX2017011009A MX2017011009A MX 2017011009 A MX2017011009 A MX 2017011009A MX 2017011009 A MX2017011009 A MX 2017011009A MX 2017011009 A MX2017011009 A MX 2017011009A MX 2017011009 A MX2017011009 A MX 2017011009A
- Authority
- MX
- Mexico
- Prior art keywords
- lipodystrophy
- apociii
- expression
- apolipoprotein
- populations
- Prior art date
Links
- 102000030169 Apolipoprotein C-III Human genes 0.000 title 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 title 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 title 1
- 208000006132 lipodystrophy Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 206010053857 partial lipodystrophy Diseases 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126439P | 2015-02-27 | 2015-02-27 | |
| PCT/US2016/019728 WO2016138355A1 (en) | 2015-02-27 | 2016-02-26 | Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011009A true MX2017011009A (es) | 2017-10-20 |
Family
ID=56789093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011009A MX2017011009A (es) | 2015-02-27 | 2016-02-26 | Modulacion de la expresion de apolipoproteina c-iii (apociii) en poblaciones con lipodistrofia. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180245076A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3270931A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018511555A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170122769A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107405358A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016222548A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017015307A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2977971A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1248522A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL253346A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2017011009A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2737719C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016138355A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018049424A1 (en) | 2016-09-12 | 2018-03-15 | Aegerion Pharmaceuticals, Inc. | Methods of detecting anti-leptin neutralizing antibodies |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| US20240033280A1 (en) * | 2020-10-02 | 2024-02-01 | Ionis Pharmaceuticals, Inc. | Methods for reducing apociii expression |
| AU2022309416A1 (en) * | 2021-07-16 | 2024-02-01 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, and preparation method and use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| ES2569248T3 (es) * | 2011-01-31 | 2016-05-09 | Cadila Healthcare Limited | Tratamiento para la lipodistrofia |
| SG194671A1 (en) * | 2011-04-27 | 2013-12-30 | Isis Pharmaceuticals Inc | Modulation of apolipoprotein ciii (apociii) expression |
| AU2014216137B2 (en) * | 2013-02-14 | 2018-05-10 | Ionis Pharmaceuticals, Inc. | Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations |
| ES2778462T3 (es) * | 2013-06-21 | 2020-08-10 | Ionis Pharmaceuticals Inc | Compuestos y métodos para modular expresión de C-III de apolipoproteína para mejorar un perfil diabético |
| US20150045431A1 (en) * | 2013-08-06 | 2015-02-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy |
-
2016
- 2016-02-26 EP EP16756424.4A patent/EP3270931A4/en not_active Withdrawn
- 2016-02-26 US US15/553,946 patent/US20180245076A1/en not_active Abandoned
- 2016-02-26 HK HK18107740.8A patent/HK1248522A1/zh unknown
- 2016-02-26 WO PCT/US2016/019728 patent/WO2016138355A1/en not_active Ceased
- 2016-02-26 AU AU2016222548A patent/AU2016222548A1/en not_active Abandoned
- 2016-02-26 CN CN201680009110.1A patent/CN107405358A/zh active Pending
- 2016-02-26 CA CA2977971A patent/CA2977971A1/en not_active Abandoned
- 2016-02-26 JP JP2017538667A patent/JP2018511555A/ja active Pending
- 2016-02-26 BR BR112017015307A patent/BR112017015307A2/pt not_active Application Discontinuation
- 2016-02-26 RU RU2017133142A patent/RU2737719C2/ru active
- 2016-02-26 KR KR1020177025758A patent/KR20170122769A/ko not_active Ceased
- 2016-02-26 MX MX2017011009A patent/MX2017011009A/es unknown
-
2017
- 2017-07-06 IL IL253346A patent/IL253346A0/en unknown
-
2019
- 2019-07-31 US US16/528,387 patent/US20200095581A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180245076A1 (en) | 2018-08-30 |
| WO2016138355A1 (en) | 2016-09-01 |
| BR112017015307A2 (pt) | 2018-01-16 |
| RU2017133142A3 (cg-RX-API-DMAC7.html) | 2019-08-12 |
| RU2017133142A (ru) | 2019-03-28 |
| CA2977971A1 (en) | 2016-09-01 |
| EP3270931A1 (en) | 2018-01-24 |
| HK1248522A1 (zh) | 2018-10-19 |
| KR20170122769A (ko) | 2017-11-06 |
| RU2737719C2 (ru) | 2020-12-02 |
| US20200095581A1 (en) | 2020-03-26 |
| CN107405358A (zh) | 2017-11-28 |
| JP2018511555A (ja) | 2018-04-26 |
| EP3270931A4 (en) | 2018-10-03 |
| AU2016222548A1 (en) | 2017-07-27 |
| IL253346A0 (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019011188A (es) | Modulacion de la expresion de apolipoproteina c-iii (apociii) en poblaciones con deficiencia de lipoproteina lipasa (lpld). | |
| PH12020500352A1 (en) | Therapeutic uses of empagliflozin | |
| BR112016024850A2 (pt) | composições e métodos para modulação da expressão 3 semelhante a antiopoietina | |
| ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
| BR112016013473A2 (pt) | Modulação da expressão de angiopoietina-tipo 3 | |
| MY162715A (en) | Modulation of apolipoprotein ciii (apociii) expression | |
| NZ707477A (en) | Activin-actrii antagonists and uses for treating bone and other disorders | |
| EA201500996A1 (ru) | Терапевтические применения эмпаглифлозина | |
| MX2022005200A (es) | Composiciones y metodos para modular la expresion de angiotensinogeno. | |
| MX350944B (es) | Modulación antisentido de la expresión de gccr. | |
| SG10201907660YA (en) | Use of short chain fatty acids in cancer prevention | |
| MX394909B (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos | |
| MX2017012426A (es) | Composiciones y metodos para modular la expresion de tmprss6. | |
| MX360639B (es) | Métodos y composiciones para modular la expresión de apolipoproteína (a). | |
| PH12013502487A1 (en) | Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents | |
| MX2016010011A (es) | Metodos para tratar y prevenir trastornos renales y trastornos del higado graso. | |
| BR112016026560A2 (pt) | Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção | |
| AU2017286811A1 (en) | Modulation of gys1 expression | |
| MX2017011009A (es) | Modulacion de la expresion de apolipoproteina c-iii (apociii) en poblaciones con lipodistrofia. | |
| PH12014500536A1 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| BR112017015840A2 (pt) | método de tratamento ou prevenção de eventos aterotrombóticos em pacientes com histórico de infarto do miocárdio | |
| TW201613639A (en) | Methods for treating cardiovascular diseases | |
| PH12017500203B1 (en) | Nutritional composition for use in promoting gut and/or liver maturation and/or repair | |
| MX2016012127A (es) | Ostreolisina, variante de la misma funcionalmente relacionada, extracto que comprende ostreolisina y usos de los mismos. |